AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19099689 — intervention group
Group type: EXPERIMENTAL
Intervention: Kawasaki disease patients with coronary artery lesions
Number of subjects: 56
Study 16352807 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (V-GCV)
Number of subjects: 0
Study 13677026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride (Erespal) 80 mg per os 3 times a day for 10 days
Number of subjects: 82
Study 13677026 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative treatment
Number of subjects: 82
Study 10873730 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal approach (n=7)
Number of subjects: 14
Study 10873730 — intervention group
Group type: COMPARATOR
Intervention: Extraperitoneal approach (n=7)
Number of subjects: 14
Study 10873730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 9118039 — intervention group
Group type: COMPARATOR
Intervention: Melphalan and Prednisone (MP)
Number of subjects: 479
Study 9118039 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone (VBMCP)
Number of subjects: 479
Study 9118039 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP
Number of subjects: 479
Study 9118039 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover VBMCP for patients failing with MP
Number of subjects: 479
Study 9118039 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 479
Study 1492852 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide 400 mg
Number of subjects: 6
Study 1492852 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide 800 mg
Number of subjects: 6
Study 1492852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3786037 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20
Study 3786037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30775944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 0
Study 30775944 — intervention group
Group type: COMPARATOR
Intervention: Diuretic therapy (DIUR-T)
Number of subjects: 0
Study 25824810 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUCLEAR System®
Number of subjects: 90
Study 25824810 — intervention group
Group type: COMPARATOR
Intervention: Versapoint® system
Number of subjects: 90
Study 23595617 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox XtraHME
Number of subjects: 45
Study 23595617 — intervention group
Group type: COMPARATOR
Intervention: Provox HME
Number of subjects: 45
Study 21226577 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 319
Study 21226577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 19143907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (10(-6) M, 10(-5) M)
Number of subjects: 12
Study 19143907 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (10(-8) M, 3.10(-8) M, 10(-7) M)
Number of subjects: 12
Study 19143907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sildenafil and doxazosin
Number of subjects: 12
Study 19143907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (10(-6) M) with EFS
Number of subjects: 12
Study 17314057 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) therapy, subcutaneous ingestion of 0.03-0.04 mg/kg once daily
Number of subjects: 24
Study 15134414 — intervention group
Group type: EXPERIMENTAL
Intervention: Theraflex-TMJ cream
Number of subjects: 52
Study 15134414 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 52
Study 12651657 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 100 microg IV
Number of subjects: 20
Study 12651657 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 20
Study 12651657 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (25 and 50 microg IV)
Number of subjects: 20
Study 12651657 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil groups (25, 50, and 100 microg IV)
Number of subjects: 20
Study 9613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 10 mg (1 ml)
Number of subjects: 100
Study 9613278 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (1 ml)
Number of subjects: 100
Study 7851372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense exercise at 5.6 m.s‐1 (0% incline)
Number of subjects: 9
Study 7851372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense exercise at +4% incline
Number of subjects: 9
Study 7851372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense exercise at +7% incline
Number of subjects: 9
Study 3200265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1200 mg per day)
Number of subjects: 68
Study 3200265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1300 mg per day)
Number of subjects: 68
Study 3200265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 3200265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 68
Study 3200265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 68
Study 4700326 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrojejunostomy
Number of subjects: 547
Study 4700326 — intervention group
Group type: COMPARATOR
Intervention: Pyloroplasty
Number of subjects: 547
Study 30738713 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous approach (PA) for management of biliary stones
Number of subjects: 91
Study 30738713 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with biliary stenosis)
Number of subjects: 91
Study 26883793 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy, Safe, and Tobacco‐free Worksites programme
Number of subjects: 20
Study 26883793 — intervention group
Group type: COMPARATOR
Intervention: Delayed‐intervention control
Number of subjects: 20
Study 26084670 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help intervention
Number of subjects: 80
Study 26084670 — intervention group
Group type: COMPARATOR
Intervention: Active comparison group exercise
Number of subjects: 80
Study 23472197 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP323 100 mg bid
Number of subjects: 71
Study 23472197 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP323 500 mg bid
Number of subjects: 71
Study 23472197 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP323 1000 mg qd
Number of subjects: 71
Study 23472197 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP323 1000 mg bid
Number of subjects: 71
Study 23472197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 21153659 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined 2‐regression model
Number of subjects: 48
Study 21153659 — intervention group
Group type: EXPERIMENTAL
Intervention: Klippel and Heil equations
Number of subjects: 48
Study 21153659 — intervention group
Group type: COMPARATOR
Intervention: 2008 Crouter 2‐regression model
Number of subjects: 48
Study 19695452 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators (ICDs)
Number of subjects: 0
Study 19695452 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical judgment in circumstances with limited data
Number of subjects: 0
Study 19695452 — intervention group
Group type: EXPERIMENTAL
Intervention: Research initiatives
Number of subjects: 0
Study 17100682 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPIDO Guiding Catheter System (Group R)
Number of subjects: 74
Study 17100682 — intervention group
Group type: COMPARATOR
Intervention: RAPIDO ADVANCE Guiding Catheter System (Group A)
Number of subjects: 74
Study 14656749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid administration in ARDS patients
Number of subjects: 19
Study 14656749 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration in ARDS patients
Number of subjects: 19
Study 14656749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid administration in patients without ARDS
Number of subjects: 19
Study 11434404 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 58
Study 11434404 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 58
Study 11434404 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram and Paroxetine
Number of subjects: 58
Study 9402077 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity to H. ducreyi
Number of subjects: 225
Study 9402077 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity to HSV-2
Number of subjects: 225
Study 9402077 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity to syphilis
Number of subjects: 225
Study 9402077 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroconversion to H. ducreyi and HSV-2
Number of subjects: 225
Study 9402077 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroconversion to HSV-2 and H. ducreyi during HIV seroconversion interval
Number of subjects: 225
Study 8357283 — intervention group
Group type: EXPERIMENTAL
Intervention: Histrionic portrayal
Number of subjects: 44
Study 8357283 — intervention group
Group type: EXPERIMENTAL
Intervention: Businesslike portrayal
Number of subjects: 44
Study 8357283 — intervention group
Group type: COMPARATOR
Intervention: Verbatim transcript
Number of subjects: 44
Study 3206197 — intervention group
Group type: EXPERIMENTAL
Intervention: Special caries preventive measures for 1 year
Number of subjects: 124
Study 3206197 — intervention group
Group type: COMPARATOR
Intervention: Routine prevention procedures
Number of subjects: 124
Study 31767947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine lubricant (Xylocaine 2%)
Number of subjects: 13
Study 31767947 — intervention group
Group type: COMPARATOR
Intervention: Standard lubricant (placebo)
Number of subjects: 13
Study 29532453 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fasting glucose
Number of subjects: 82
Study 29532453 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin A1c (A1c)
Number of subjects: 82
Study 29532453 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 82
Study 29532453 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher subscapular skinfolds
Number of subjects: 82
Study 28501287 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 266
Study 28501287 — intervention group
Group type: COMPARATOR
Intervention: Conventional pain management
Number of subjects: 266
Study 25897797 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodromal Detection and Treatment program (including information campaigns and detection teams)
Number of subjects: 0
Study 25897797 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group from Bergen and Østfold)
Number of subjects: 0
Study 23103936 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training for 12 weeks
Number of subjects: 100
Study 23103936 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation training for 12 weeks
Number of subjects: 100
Study 23103936 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 100
Study 20889164 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer chelation treatment
Number of subjects: 767
Study 20889164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 767
Study 18336963 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinrix vaccine administered according to a 0-, 1-, and 6-month schedule.
Number of subjects: 59
Study 16464519 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg for 10 days)
Number of subjects: 20
Study 16464519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15690118 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Sexual Health Intervention (ESHI)
Number of subjects: 147
Study 15690118 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 147
Study 11737908 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term infusion of corticosteroids
Number of subjects: 20000
Study 11737908 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20000
Study 9240487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Difficulties Scale (CDS)
Number of subjects: 63
Study 8477564 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Contin tablets 90 mg
Number of subjects: 151
Study 8477564 — intervention group
Group type: COMPARATOR
Intervention: Oramorph SR tablets 30 mg
Number of subjects: 151
Study 8477564 — intervention group
Group type: COMPARATOR
Intervention: Oramorph SR tablets 90 mg
Number of subjects: 151
Study 8477564 — intervention group
Group type: COMPARATOR
Intervention: MS Contin tablets 30 mg
Number of subjects: 151
Study 8477564 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Contin tablets
Number of subjects: 151
Study 8477564 — intervention group
Group type: COMPARATOR
Intervention: Oramorph SR tablets
Number of subjects: 151
Study 2962005 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 56
Study 2962005 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 56
Study 2962005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31952145 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening activity program (low to moderate intensity physical activity)
Number of subjects: 0
Study 31952145 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening activity program
Number of subjects: 0
Study 31952145 — intervention group
Group type: COMPARATOR
Intervention: Control (non-gardening) group
Number of subjects: 0
Study 31138315 — intervention group
Group type: EXPERIMENTAL
Intervention: magnesium citrate
Number of subjects: 162
Study 31138315 — intervention group
Group type: EXPERIMENTAL
Intervention: magnesium oxide
Number of subjects: 162
Study 31138315 — intervention group
Group type: EXPERIMENTAL
Intervention: magnesium sulfate
Number of subjects: 162
Study 31138315 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 162
Study 27889103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathectomy (excision of T3 ganglia)
Number of subjects: 60
Study 27889103 — intervention group
Group type: COMPARATOR
Intervention: Sympathicotomy (interruption of sympathetic chain at T2 to T3 level with ganglion sparing)
Number of subjects: 60
Study 25306888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal budesonide
Number of subjects: 24
Study 25306888 — intervention group
Group type: COMPARATOR
Intervention: Nasal placebo
Number of subjects: 24
Study 24124328 — intervention group
Group type: EXPERIMENTAL
Intervention: AN-PEP
Number of subjects: 16
Study 24124328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21504886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco dependence treatment RCT incorporating behavioral counseling and nicotine replacement
Number of subjects: 0
Study 21504886 — intervention group
Group type: COMPARATOR
Intervention: Women who agreed to enroll in the RCT
Number of subjects: 0
Study 19567215 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0
Study 19567215 — intervention group
Group type: COMPARATOR
Intervention: Efalizumab
Number of subjects: 0
Study 19567215 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study 17698902 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 4 IU subcutaneously every other day for 3 months
Number of subjects: 22
Study 15507059 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d
Number of subjects: 1392
Study 15507059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1392
Study 12536693 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil 100 mg.d‐1
Number of subjects: 58
Study 9270084 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic alpha1-receptor blockade (BLK)
Number of subjects: 13
Study 9270084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study 9270084 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mm Hg during BLK
Number of subjects: 13
Study 9270084 — intervention group
Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Number of subjects: 13
Study 9270084 — intervention group
Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP) during PLA
Number of subjects: 13
Study 9270084 — intervention group
Group type: EXPERIMENTAL
Intervention: BLK
Number of subjects: 13
Study 7892725 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal impulse lithotripsy (EIL) combined with supravesical endourological techniques
Number of subjects: 1311
Study 7892725 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray endoscopy
Number of subjects: 1311
Study 3301710 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg femoxetine daily for 16 weeks
Number of subjects: 73
Study 3301710 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 16 weeks
Number of subjects: 73
Study 3301710 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine in subgroups of patients with obesity problems for more than 20 years
Number of subjects: 73
Study 3301710 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine in subgroups of patients previously in anorectic treatment
Number of subjects: 73
Study 3301710 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine
Number of subjects: 73
Study 31617649 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin (two capsules per day for 28 days)
Number of subjects: 40
Study 31617649 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules per day for 28 days)
Number of subjects: 40
Study 28554732 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 32
Study 25629740 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of subcutaneous icatibant
Number of subjects: 27
Study 25629740 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (intravenous prednisolone 500 mg plus clemastine 2 mg)
Number of subjects: 27
Study 23339387 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte and monocyte/macrophage adsorptive apheresis (GMA)
Number of subjects: 98
Study 23339387 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LCAP)
Number of subjects: 98
Study 23339387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GMA and LCAP
Number of subjects: 98
Study 23339387 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 98
Study 20697417 — intervention group
Group type: EXPERIMENTAL
Intervention: HDHK program (n=27 fathers, n=39 children)
Number of subjects: 53
Study 20697417 — intervention group
Group type: EXPERIMENTAL
Intervention: HDHK program
Number of subjects: 53
Study 20697417 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=26 fathers, n=32 children)
Number of subjects: 53
Study 19860993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 19860993 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 16923426 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential extraostial PV isolation
Number of subjects: 100
Study 16923426 — intervention group
Group type: COMPARATOR
Intervention: Segmental ostial PV isolation
Number of subjects: 100
Study 16923426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 100
Study 12577156 — intervention group
Group type: COMPARATOR
Intervention: Routine endotracheal suctioning (RES)
Number of subjects: 383
Study 12577156 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand minimally invasive airway suctioning (MIAS)
Number of subjects: 383
Study 11146823 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 15
Study 11146823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8923356 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfasalazine (SSZ)
Number of subjects: 137
Study 8923356 — intervention group
Group type: EXPERIMENTAL
Intervention: gold sodium thiomalate (GSTM)
Number of subjects: 137
Study 8923356 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 137
Study 8923356 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with RA
Number of subjects: 137
Study 8923356 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline sIL-2R
Number of subjects: 137
Study 1402071 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus gentamicin
Number of subjects: 32
Study 1402071 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus aztreonam
Number of subjects: 32
Study 1402071 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole added to non-responders
Number of subjects: 32
Study 3887852 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395
Study 3887852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study 30139568 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis with diclofenac + Thiocolchicoside gel (Group 1)
Number of subjects: 60
Study 30139568 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound therapy with non-therapeutic gel (Group 2)
Number of subjects: 60
Study 29570027 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-silane-pretreated mode
Number of subjects: 0
Study 29570027 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane-pretreated mode
Number of subjects: 0
Study 29570027 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhese Universal, Clearfil Universal Bond, Single Bond Universal (all in silane-pretreated mode)
Number of subjects: 0
Study 26494876 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 20
Study 26494876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25081290 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg acetazolamide
Number of subjects: 24
Study 25081290 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 24
Study 22215002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 42